Evidence Skin Lab Special Edition
May 27, 2026
Oral collagen peptides are not proven anti-aging treatment. The literature looks positive when all trials are pooled, especially for skin hydration and elasticity, but most of the positive signal comes from studies that are industry-funded, company-authored, product-supplied, branded-ingredient trials, or too commercially entangled to treat as independent proof.
Plain-language verdict
The most important funding-sensitive meta-analysis found that collagen supplements looked beneficial overall, but non-funded studies and higher-quality studies did not show significant benefit for hydration, elasticity, or wrinkles. That is the central finding.
This does not mean collagen is useless. The most reasonable interpretation is that some hydrolyzed collagen products, particularly low-molecular-weight fish-derived peptides enriched in Gly-Pro-Hyp, Pro-Hyp, Gly-Pro, or Gly-X-Y tripeptides, may produce a small hydration signal and possibly a modest elasticity signal after 8-12 weeks. The data do not support claims like “reverses aging,” “rebuilds collagen,” or “clinically proven wrinkle reduction” as a general category claim.
A fair consumer-facing claim would be: “may support skin hydration and elasticity.” Anything stronger needs an independent finished-product RCT.
Abstract
Background
Oral collagen peptide supplements are widely marketed for skin hydration, elasticity, wrinkles, and “beauty from within.” Many randomized controlled trials report benefit, but the field is heavily commercial. Funding source matters because cosmetic supplement trials are vulnerable to selective outcome reporting, small sample sizes, surrogate endpoints, product-specific formulations, and publication bias.
Objective
To review human randomized evidence for oral collagen peptides in cosmetic skin outcomes and to compare the overall industry-heavy literature with more independent non-industry-funded evidence.
Methods
We reviewed PubMed-indexed randomized controlled trials and recent systematic reviews/meta-analyses of oral hydrolyzed collagen/collagen peptide supplementation for skin hydration, elasticity, wrinkling, dermal density, and related cosmetic endpoints. Studies were classified by funding risk: independent/non-industry, unclear, industry-funded, industry-affiliated, branded-ingredient, or multi-ingredient commercial product. We report published meta-analytic estimates and performed a secondary random-effects re-analysis using study-level standardized mean differences and confidence intervals extracted from Pu et al. 2023 forest plots. This is a website-ready systematic evidence review, not a registered PROSPERO review.
Results
Pu et al. 2023 included 26 RCTs and 1,721 participants and reported significant improvements in hydration and elasticity. The pooled SMDs were 0.63 for hydration and 0.72 for elasticity. Danessa et al. 2025 included 10 RCTs and 646 participants and reported hydration SMD 1.25 and elasticity SMD 0.61, with moderate heterogeneity and generally unclear risk of bias. Myung and Park 2025 included 23 RCTs and 1,474 participants; overall pooled results were positive, but trials not receiving company funding showed no significant benefit for hydration, elasticity, or wrinkles, and high-quality studies also showed no significant benefit.
The most independent accessible non-industry RCT, Guadanhim et al. 2023, tested oral hydrolyzed collagen 5 g/day for 6 months in 56 postmenopausal women with dermatoporosis and found no significant benefit on clinical scores, quality of life, dermal elasticity, dermal thickness, echogenicity, histology, or immunohistochemistry.
Our secondary re-analysis of Pu et al. forest-plot values reproduced a positive overall signal: hydration SMD 0.63 and elasticity SMD 0.72. Fish/marine-derived collagen remained directionally positive: hydration SMD 0.71 including combination products and 0.65 excluding explicit combination formulas; elasticity SMD 0.76 including combinations and 0.56 excluding explicit combinations. This fish signal is interesting but mostly comes from industry-linked or unclear-funding trials.
Conclusion
The overall evidence suggests a possible small benefit for skin hydration and maybe elasticity, especially with low-molecular-weight fish-derived peptides. Independent low-bias evidence does not yet prove a clinically meaningful anti-aging effect. The honest clinical position is: oral collagen peptides may help some skin-barrier and hydration measures, but wrinkle reversal and dermal rebuilding claims are not supported by independent low-bias evidence.
Introduction
Collagen is the dominant structural protein in the dermis, and collagen fragmentation and reduced synthesis are part of intrinsic and extrinsic skin aging. The commercial argument is simple: ingest collagen peptides, absorb amino acids and short peptides, stimulate fibroblasts, and improve the skin. The biology is plausible, but plausible biology is not clinical proof.
Dermatology has seen this pattern before. A treatment can have a reasonable mechanism, small biomarker changes, and several positive commercial trials, yet still fail when tested independently or under stricter conditions. Oral collagen sits in that gray zone. It is probably safe for most healthy adults, but the marketing is well ahead of the independent evidence.
The key question is not whether any collagen trial is positive. Many are. The better question is: what remains after removing industry-funded and company-affiliated trials?
Methods
Review question
Do oral collagen peptides improve cosmetic skin outcomes in humans, and does the conclusion change when industry-funded or company-affiliated trials are separated from more independent evidence?
Eligibility criteria
Included studies were human randomized or controlled clinical trials of oral collagen, hydrolyzed collagen, collagen peptides, collagen tripeptides, or collagen-containing supplements with skin outcomes. Eligible outcomes included hydration, elasticity, wrinkle measures, roughness, desquamation, dermal density/thickness, transepidermal water loss, natural moisturizing factor, ceramides, histology, and patient-reported skin appearance.
Excluded from the independent low-bias evidence set were studies with company funding, company employees as authors, company-provided products, branded-ingredient sponsorship, commercial multi-ingredient formulations where collagen could not be isolated, or inaccessible funding/conflict statements.
Evidence sources
The review was based on PubMed-indexed trials, open full-text articles, PubMed records, and recent meta-analyses. The main synthesis papers were Pu et al. 2023, Danessa et al. 2025, and Myung & Park 2025. The key independent full-text trial was Guadanhim et al. 2023.
Funding classification
Trials were classified as independent/non-industry, industry-funded, industry-affiliated, branded/commercial, or unclear. A strict approach was used. “No external funding” did not automatically mean independent if most authors were employees of the company developing the ingredient.
- Independent/non-industry: no commercial funding, no company authorship, and no product-company support identified in the article.
- Industry-funded: company funding or grant support.
- Industry-affiliated: company employees among authors or product developed/supplied by company authors.
- Branded/commercial: branded ingredient or finished-product trial with commercial involvement.
- Unclear: funding/conflict statement not accessible or incomplete.
Statistical approach
Published meta-analytic estimates were extracted from Pu et al. 2023, Danessa et al. 2025, and Myung & Park 2025. For a secondary aggregate re-analysis, study-level SMDs and 95% confidence intervals were extracted from Pu et al. forest plots. Standard errors were estimated using SE = (upper CI - lower CI) / 3.92.
Random-effects pooling was then performed for hydration and elasticity overall, fish/marine-derived collagen, fish/marine-derived collagen excluding explicit combination formulas, and non-fish/unknown/chicken/porcine studies. These analyses are not a replacement for a full raw-data meta-analysis. They are a transparent re-check of the published forest-plot signal.
Results
Published meta-analyses
| Review | Scope | Main quantitative result | Funding-sensitive interpretation |
|---|---|---|---|
| Pu et al. 2023 | 26 RCTs; 1,721 participants | Hydration SMD 0.63, 95% CI 0.38-0.88; elasticity SMD 0.72, 95% CI 0.40-1.03 | Positive overall, but pooled many industry-linked or unclear-funding studies. The authors also identified biases and called for larger RCTs. |
| Danessa et al. 2025 | 10 RCTs; 646 participants | Hydration SMD 1.25, 95% CI 0.77-1.74; elasticity SMD 0.61, 95% CI 0.21-1.02 | Positive, but moderate heterogeneity, unclear risk of bias, female-heavy samples, and small number of studies. |
| Myung & Park 2025 | 23 RCTs; 1,474 participants | Overall pooled results positive; non-funded studies showed no significant benefit; high-quality studies showed no significant benefit | Most important analysis for clinical interpretation. It directly tests the funding-bias problem and substantially weakens the category claim. |
Secondary re-analysis of Pu et al. forest-plot data
| Outcome | Subset | k | Random-effects SMD | 95% CI | p value | I2 |
|---|---|---|---|---|---|---|
| Skin hydration | All extracted studies | 19 | 0.630 | 0.380 to 0.881 | <0.0001 | 69.7% |
| Skin hydration | Fish/marine-derived, including combination formulas | 11 | 0.706 | 0.421 to 0.990 | <0.0001 | 56.7% |
| Skin hydration | Fish/marine-derived, excluding explicit combination formulas | 8 | 0.645 | 0.328 to 0.961 | <0.0001 | 53.4% |
| Skin hydration | Non-fish/unknown/chicken/porcine | 8 | 0.538 | 0.125 to 0.952 | 0.0108 | 75.2% |
| Skin elasticity | All extracted studies | 19 | 0.716 | 0.403 to 1.029 | <0.0001 | 83.6% |
| Skin elasticity | Fish/marine-derived, including combination formulas | 10 | 0.761 | 0.293 to 1.228 | 0.0014 | 84.3% |
| Skin elasticity | Fish/marine-derived, excluding explicit combination formulas | 7 | 0.559 | 0.344 to 0.775 | <0.0001 | 0.0% |
| Skin elasticity | Non-fish/unknown/chicken/porcine | 9 | 0.664 | 0.235 to 1.093 | 0.0024 | 83.2% |
The pooled numbers look good, including for fish-derived peptides. The problem is not the arithmetic. The problem is the source of the data. The trials driving these pooled estimates are mostly commercial, branded, product-supplied, combination formulas, or unclear. When funding source is handled directly, the conclusion weakens.
Independent and lower-bias evidence
Guadanhim et al. 2023: most independent accessible RCT, negative
This was a randomized, double-blind, placebo-controlled factorial trial in 56 postmenopausal women, age 60-93, with stage I dermatoporosis. The oral arm used hydrolyzed collagen 5 g/day for 6 months. The collagen was described as bovine and porcine type I peptides, approximately 2 kDa. A topical hydrolyzed collagen arm was also tested.
Results were negative. There was no significant benefit for clinical scores, quality of life, dermal elasticity, dermal thickness, echogenicity, histology, or immunohistochemistry. The PubMed abstract reports p > 0.1 across efficacy parameters. This is not a perfect consumer-beauty trial because it studied forearm dermatoporosis in older women, not facial photoaging in middle-aged cosmetic consumers. Still, it is an important independent stress test, and it failed.
Sangsuwan & Asawanonda 2020/2021: possible non-industry positive signal, not fully verified
This trial is often cited as a positive marine collagen study. It reportedly used 5 g/day marine collagen hydrolysate for 4 weeks in postmenopausal women and found improved elasticity, especially in sun-exposed cheek skin. The issue is access: full text and complete funding/conflict statements were not legally accessible during this review. Therefore, it should be treated as promising but not fully verified.
Seong et al. 2024 and Lee et al. 2025: possible non-funded/lower-bias signals, not enough to settle the question
Recent low-molecular-weight collagen peptide studies are reported as positive and may have no disclosed financial support. However, full composition, product source, and funding details need complete full-text verification before they can be used as independent evidence. They are candidates for follow-up review, not enough to override the funding-sensitive meta-analysis.
Industry-funded and company-affiliated evidence
The commercial literature is much more positive. This matters because if the question is “can a specific collagen product show a signal under cosmetic testing conditions?” the answer is yes. If the question is “is the category independently proven?” the answer is no.
| Study | Funding class | Agent | Dose/duration | Result | Comment |
|---|---|---|---|---|---|
| Proksch et al. 2014a | Branded/industry-linked evidence base | Specific collagen peptides, VERISOL-type; porcine type I; approx. 2 kDa | 2.5 g or 5 g/day for 8 weeks | Improved elasticity; hydration/TEWL/roughness less consistent | Positive, but not independent low-bias evidence. |
| Proksch et al. 2014b | Branded/industry-linked evidence base | Specific bioactive collagen peptides, VERISOL-type | 2.5 g/day for 8 weeks | Reduced eye wrinkle volume and dermal matrix markers | Often cited commercially; funding context limits independence. |
| Asserin et al. 2015 | Branded ingredient / Peptan-Rousselot context | Fish or porcine collagen peptides | 10 g/day for 8-12 weeks | Improved hydration and dermal collagen parameters | Useful product data, not independent proof. |
| Kim et al. 2018 | Industry-affiliated/product-supplied | Low-molecular-weight fish collagen from sutchi catfish; >15% Gly-X-Y tripeptides; 3% Gly-Pro-Hyp | 1 g/day for 12 weeks | Improved hydration, wrinkles, selected elasticity metrics | Strong fish-peptide signal, but company involvement. |
| Jung et al. 2021 | Company-employee trial | Fish-scale APCP from Nemipterus virgatus; >15% tripeptides; 3% Gly-Pro-Hyp | 1 g/day for 12 weeks | Improved moisture, roughness, NMF, ceramide markers | Interesting barrier data; most authors were Amorepacific employees. |
| Lee et al. 2023 CPNS | Industry-funded | Tilapia fish-scale CPNS; <500 Da low-MW fraction; 4% Gly-Pro; Pro-Hyp present | 1.65 g/day for 12 weeks | Improved hydration/desquamation by 4 weeks, wrinkles/elasticity later | One of the better fish signals; supported by Nongshim. |
| Evans et al. 2021 | Industry-funded | Vinh Wellness hydrolyzed freshwater marine collagen | 10 g/day for 12 weeks | 35% wrinkle-score reduction from baseline; right-face wrinkle advantage vs placebo; subgroup elasticity signal | Commercial fish collagen trial; funded by Vinh Hoan. |
| Nomoto & Iizaka 2020 | Industry-supported | Oral nutrition supplement containing collagen peptides | 10-12 g/day for 8 weeks | Improved hydration and elasticity in older hospitalized adults | Open-label and industry-supported; not cosmetic population. |
| Czajka et al. 2018 | Commercial multi-ingredient | Hydrolyzed fish collagen plus vitamins, antioxidants, glucosamine, chondroitin, L-carnitine, other actives | 90 days | Improved elasticity and self-perceived skin outcomes | Cannot isolate collagen effect. |
| Bolke et al. 2019 | Commercial multi-ingredient | Collagen peptides plus vitamin C, zinc, vitamin E, biotin and other co-actives | 12 weeks plus follow-up | Reported hydration, elasticity, roughness, density improvements | Product evidence, not collagen-only proof. |
Fish-derived peptides: is there a signal?
Yes, there is a signal. The fish/marine subgroup remains positive in the industry-heavy dataset, and several of the best-looking low-dose trials use fish-derived peptides.
The most plausible active pattern is not generic “fish collagen.” It is low-molecular-weight, enzymatically hydrolyzed type I collagen with measurable short peptides.
- Gly-Pro-Hyp
- Pro-Hyp
- Gly-Pro
- Gly-X-Y tripeptide fraction
The stronger fish-derived trials typically use 1-2 g/day when the peptide profile is concentrated, or 5-10 g/day when the product is less specifically characterized. The most attractive commercial profile is a 1-2.6 g/day fish-derived low-molecular-weight collagen peptide product with documented molecular-weight distribution and quantified marker peptides.
But the fish signal is still commercially entangled. CPNS was supported by Nongshim. Jung's APCP study involved Amorepacific employees and Aestura-provided product. Kim 2018 had product-company involvement. Evans 2021 was funded by Vinh Hoan. The pattern is promising enough to justify a proper independent RCT, not enough to claim independent proof.
Endpoint-by-endpoint interpretation
Skin hydration
This is the most believable endpoint. Hydration is responsive to small changes in stratum corneum water content, environmental conditions, product use, and measurement technique. Positive effects in collagen trials may be real, but the clinical relevance is not always obvious. A corneometer improvement is not the same as visibly younger skin.
Evidence grade: possible small benefit, low-to-moderate certainty if industry trials are included; low certainty when restricted to independent low-bias evidence.
Skin elasticity
Elasticity is more complicated. Cutometer measures can vary by site, age, skin thickness, season, hydration state, and analytic parameter. The pooled elasticity signal is positive, but heterogeneity is high in the overall data. Fish-derived peptides excluding explicit combination formulas looked surprisingly consistent in the secondary re-analysis, but those trials are too commercially entangled to settle the question.
Evidence grade: possible modest benefit, low certainty.
Wrinkles
Wrinkle claims are the weakest commercially important endpoint. Some trials report wrinkle improvement, but these are commonly industry-funded, use image-analysis endpoints, subgroup effects, or within-group comparisons. Myung & Park found that non-funded studies did not show significant wrinkle benefit.
Evidence grade: not proven.
Dermal density, collagen synthesis, histology
These endpoints sound more impressive but are not convincingly established independently. Some commercial trials report dermal density, collagen fragmentation, or biopsy markers, but the independent dermatoporosis trial showed no benefit on histology or immunohistochemistry.
Evidence grade: weak.
Safety
Hydrolyzed collagen peptides appear generally safe in short RCTs, with few adverse events reported. That does not remove the need for fish allergy labeling, heavy-metal testing for marine sources, microbiology, identity testing, molecular-weight profile, and contaminant specifications.
Evidence grade for short-term safety: reasonably reassuring.
Discussion
The collagen supplement literature has two different stories.
The first story is the marketing story: multiple RCTs, positive pooled estimates, skin hydration improves, elasticity improves, fish peptides look good, and the product is safe. This story is not fabricated. There is a real body of positive published data.
The second story is the clinical evidence story: most of the positive data are commercially entangled, many trials are small, several use product-specific formulations or co-actives, and the outcomes are often surrogate cosmetic measurements. When a meta-analysis directly separates studies by funding source and quality, the benefit disappears in non-funded and high-quality subgroups.
That does not prove the true effect is zero. It means the true effect is probably smaller than the marketing literature suggests, and it may depend heavily on the exact peptide profile, dose, duration, population, season, and endpoint.
From a dermatologist's perspective, the hierarchy is clear: sunscreen, retinoids, procedures, and proven topical regimens have a much stronger evidence base for photoaging; oral collagen may be reasonable as an adjunct for patients who understand the uncertainty and are not expecting wrinkle reversal; and it should not be sold as an anti-aging treatment unless the finished product has its own independent RCT.
Practical product conclusion
If developing a product, the best scientific bet is fish-derived low-molecular-weight collagen peptides, not generic collagen powder.
Recommended specification
- Source: fish skin or scales, preferably type I collagen.
- Dose: 1-2.6 g/day for a stick-pack product.
- Molecular weight: documented, ideally average ≤500-1,000 Da or a clearly characterized low-MW fraction.
- Tripeptide content: target ≥15% Gly-X-Y if possible.
- Marker peptides: quantify Gly-Pro-Hyp, Pro-Hyp, and Gly-Pro.
- Testing: heavy metals, arsenic species if relevant, mercury, cadmium, lead, microbiology, allergens, identity, amino-acid profile, peptide profile, stability.
Recommended claim ceiling without a new independent finished-product RCT
- “May support skin hydration.”
- “May support skin elasticity.”
- “Helps maintain healthy-looking skin.”
Claims to avoid
- “Clinically proven anti-aging.”
- “Reduces wrinkles” as a broad category claim.
- “Rebuilds dermal collagen.”
- “Reverses skin aging.”
- “Dermatologist-proven alternative to procedures.”
Final clinical conclusion
Oral collagen peptides are not obvious snake oil, but the category is overmarketed. The best reading is a possible small hydration benefit and a less certain elasticity benefit, mainly shown in industry-heavy trials. Independent low-bias evidence is too sparse and too weak to support anti-aging or wrinkle-reversal claims.
A scientifically honest product can be built around low-molecular-weight fish collagen peptides, but the product should be marketed carefully. If the goal is to make a serious evidence-based brand, the move is to run an independent, preregistered, blinded RCT on the finished product with hydration, elasticity, wrinkle imaging, and patient-visible endpoints.
References
- Pu SY, Huang YL, Pu CM, et al. Effects of Oral Collagen for Skin Anti-Aging: A Systematic Review and Meta-Analysis. Nutrients. 2023;15(9):2080. PMID: 37432180. https://pubmed.ncbi.nlm.nih.gov/37432180/
- Myung SK, Park Y. Effects of Collagen Supplements on Skin Aging: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. The American Journal of Medicine. 2025;138(9):1264-1277. PMID: 40324552. https://pubmed.ncbi.nlm.nih.gov/40324552/
- Danessa G, Notario D, Regina R. Effects of collagen-based supplements on skin's hydration and elasticity during ageing: A systematic review and meta-analysis. Indian J Dermatol Venereol Leprol. 2025;91:730-740. https://ijdvl.com/effects-of-collagen-based-supplements-on-skins-hydration-and-elasticity-a-systematic-review-and-meta-analysis/
- Guadanhim LRS, Miot HA, Soares JLM, et al. Efficacy and Safety of Topical or Oral Hydrolyzed Collagen in Women with Dermatoporosis: A Randomized, Double-Blind, Factorial Design Study. Dermatol Ther (Heidelb). 2023;13(2):523-534. PMID: 36547800. https://pubmed.ncbi.nlm.nih.gov/36547800/
- Proksch E, Segger D, Degwert J, Schunck M, Zague V, Oesser S. Oral supplementation of specific collagen peptides has beneficial effects on human skin physiology. Skin Pharmacol Physiol. 2014;27(1):47-55. https://pubmed.ncbi.nlm.nih.gov/23949208/
- Lee H, Kim E, Lee M, Ahn H, Son S. Oral intake of collagen peptide NS improves hydration, elasticity, desquamation, and wrinkling in human skin: a randomized, double-blinded, placebo-controlled study. Food Funct. 2023. https://pubs.rsc.org/en/content/articlehtml/2023/fo/d2fo02958h
- Kim DU, Chung HC, Choi J, Sakai Y, Lee BY. Oral Intake of Low-Molecular-Weight Collagen Peptide Improves Hydration, Elasticity, and Wrinkling in Human Skin. Nutrients. 2018;10(7):826. https://pubmed.ncbi.nlm.nih.gov/29949889/
- Jung K, Kim SH, Joo KM, et al. Oral Intake of Enzymatically Decomposed AP Collagen Peptides Improves Skin Moisture and Ceramide and Natural Moisturizing Factor Contents. Nutrients. 2021;13(12):4372. https://www.mdpi.com/2072-6643/13/12/4372
- Evans M, Lewis ED, Zakaria N, Pelipyagina T, Guthrie N. A randomized, triple-blind, placebo-controlled, parallel study to evaluate freshwater marine collagen on wrinkles and elasticity. J Cosmet Dermatol. 2021;20(3):825-834. https://pubmed.ncbi.nlm.nih.gov/32799362/
- Nomoto T, Iizaka S. Effect of an Oral Nutrition Supplement Containing Collagen Peptides on Stratum Corneum Hydration and Skin Elasticity in Hospitalized Older Adults. Adv Skin Wound Care. 2020;33(4):186-191. https://pubmed.ncbi.nlm.nih.gov/32195722/
- Czajka A, Kania EM, Genovese L, et al. Daily oral supplementation with collagen peptides combined with vitamins and other bioactive compounds improves skin elasticity and joint/general wellbeing. Nutr Res. 2018;57:97-108. https://pubmed.ncbi.nlm.nih.gov/30122200/